OVERVIEW Non-muscle invasive bladder cancer (NMIBC) accounts for most newly diagnosed bladder cancers. The condition has a wide range of progression and recurrence rates that are clinically understood and managed through established risk stratification models. Patients with high-risk NMIBC (HR-NMIBC) are at the greatest risk for recurrence after treatment and progression to metastatic disease. Join us for a lively, interactive session that will address risk-stratifying patients, identifying eligibility for treatment and maintenance, optimally selecting treatments for patients with HR-NMIBC, and recognizing emerging regimens that could shift the treatment paradigm.
6:50 pm: Current Treatment Landscape for Management of HR-NMIBC
7:10 pm: Immunotherapy-Based Treatment Regimens for the Management of HR-NMIBC
7:30 pm: Emerging Therapies and the Clinical Data
7:50 pm: Panel Discussion and Audience Q&A
8:00 pm: Program Conclusion
TARGET AUDIENCE This activity is intended for urologists, oncologists, including uro-oncologists, pathologists, and other clinicians who care for individuals with bladder cancer.
ACCREDITATION STATEMENT In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
For Physicians Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
GOAL STATEMENT The goal of this activity is for learners to be better able to improve their understanding of immunotherapy-based regimens in the care of patients with HR-NMIBC.
LEARNING OBJECTIVES Upon completion of this activity, participants will: Have increased knowledge regarding the Identification of patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) Role of immunotherapy combination strategies in the management of HR-NMIBC Clinical data associated with the emerging immunotherapy combination strategies for the management of HR-NMIBC
Have greater competence related to Diagnosing and risk-stratifying patients with HR-NMIBC using up-to-date guidelines
Demonstrate greater confidence in their ability to Identify the urologist’s role in the management of patients with HR-NMIBC
Supported by an independent educational grant from AstraZeneca Pharmaceuticals LP and Pfizer.
